Arcadia Biosciences, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Arcadia Biosciences (market cap ~$5.7M) closed a $4M private placement in June 2026, ending Q2 with $4.2M cash. Q2 2026 revenues were $1.443M (flat vs. $1.455M in Q2 2025); first-half 2026 revenues fell 4% to $2.543M. Operating cash burn improved to $319K in Q2 and $1.418M for H1 2026. However, net loss widened to $10.7M for H1 2026 due to $5.4M valuation loss on the PIPE, $4.3M unrealized loss on Above Food stock, and $2.9M loss on January 2026 inducement offer. CEO cited inflection point in Zola product (July sales $740K, exceeding $1M by early August) with Q4 2026 new 1-liter espresso launch planned and three additional products targeted for H1 2027.
Why this rating
Equity raise of $4M (70% of company market cap) is transformational for survival; offset by large non-cash valuation charges. Near-term cash runway improved materially; product momentum signals recovery path.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.